Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Variant Bio is raising $104,999,883.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Andrew Farnum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Variant Bio
Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits.

To learn more about Variant Bio, visit http://www.variantbio.com/

Contact:
Andrew Farnum, Chief Executive Officer
206-719-6382
https://www.linkedin.com/in/andrew-farnum-4b180a1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved